NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc. Stock News
$0.545
+0.0200 (+3.81%)
At Close: Apr 24, 2024
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
06:00am, Monday, 01'st Aug 2022
NEW YORK , Aug. 1, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q1 2022 Results - Earnings Call Transcript
10:20am, Monday, 16'th May 2022
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Tom Galassi - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
06:00am, Monday, 02'nd May 2022
NEW YORK , May 2, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company wil
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript
02:29pm, Monday, 28'th Mar 2022
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript
BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update
06:00am, Monday, 14'th Mar 2022
NEW YORK, March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company w
BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference
09:09pm, Monday, 28'th Feb 2022 PR Newswire
NEW YORK, Feb. 28, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA…
Brainstorm Cell gets Brazilian patent covering methods of manufacturing NurOwn
02:28pm, Tuesday, 15'th Feb 2022 Seeking Alpha
Brainstorm Cell Therapeutics (BCLI) said the Brazilian Patent Office granted a patent covering a method of manufacturing MSC-NTF cells (NurOwn).The application is titled, "A method…
BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit
07:00am, Thursday, 27'th Jan 2022
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
07:00am, Tuesday, 04'th Jan 2022
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph
Amyotrophic Lateral Sclerosis Market Qualitative Insights Key Enhancement & Share Analysis to 2027|Brainstorm Cell Therapeutics, Sanofi, Biogen
09:31am, Friday, 24'th Dec 2021 OpenPR
The market is being driven by a growing senior population, increased awareness of ALS, and an increasing incidence rate. The high cost of ALS therapy, on the other hand, may be an obstacle to the market throughout the projection period. North
Striking Stock: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), Oragenics, Inc. (AMEX:OGEN)
04:40am, Friday, 24'th Dec 2021 Stock Equity
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) with the stream of 9.41% also noticed, India Oragenics, Inc. (AMEX:OGEN) encountered a rapid change of -2.47% in the last hour of Thursdays trading session. The post Striking Stock: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), Oragenics, Inc. (AMEX:OGEN) appeared first on Stocks Equity .
Zacks: Analysts Anticipate Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to Announce -$0.23 Earnings Per Share
02:14pm, Saturday, 18'th Dec 2021 Dakota Financial News
Equities research analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report ($0.23) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Brainstorm Cell Therapeutics reported []
Volume Movers: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), SentinelOne, Inc. (NYSE:S)
12:01am, Wednesday, 15'th Dec 2021 Stock Equity
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) with the stream of -14.74% also noticed, India SentinelOne, Inc. (NYSE:S) encountered a rapid change of -1.46% in the last hour of Tuesdays trading session. The post Volume Movers: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), SentinelOne, Inc. (NYSE:S) appeared first on Stocks Equity .
Millennium Management LLC Acquires New Position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
10:14am, Wednesday, 08'th Dec 2021 Transcript Daily
Millennium Management LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 371,460 shares of the biotechnology companys stock, valued at approximately $1,412,000. Millennium Management LLC owned 1.02% of Brainstorm Cell Therapeutics []
-$0.23 EPS Expected for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) This Quarter
11:06pm, Sunday, 05'th Dec 2021 Transcript Daily
Equities analysts forecast that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will announce ($0.23) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Brainstorm Cell Therapeutics reported earnings []